Access and Models to increase the availability of innovative drugs with examples - Prof. Rok Hren


Rok Hren


There are many payment models to increase innovative treatment access and we need to put all of them contents of the healthcare system and its possibilities. Prof. Hren is showing us different examples of access and payment models from countries and healthcare systems.


Rok Hren, PhD, MSc IHP (HE) is currently a Head of Laboratory Diagnostics, Point.of.Care and Molecular Diagnostics in the Adriatic Region within Siemens Healthineers and has more than 15 years of commercial experience in the pharmaceutical industry, with more than 12 years on a board level in both (i) line management, which has included full P&L responsibility for operations in Slovenia and Romania, and (ii) leadership regional functions in Central and Eastern Europe. He has also served as the Assistant Professor at the University of Ljubljana, Slovenia, and as a Director of a consulting company, Hren & Partner doo, Slovenia. 

He is President of the ISPOR Slovenia Regional Chapter, a Chair of the ISPOR Central and Eastern Europe Consortium Research Committee, and a member of the ISPOR Health Science Policy Council Science and Research Committee. He was a faculty member of the ISPOR Short Course Program "Risk-Sharing/Performance- Based Arrangements in Central and Eastern Europe: Implementation of Managed Entry Agreements" at the ISPOR 18th, 19th, and 20th Annual European Congresses, and a co-chair of the ISPOR Research Review Committee at the ISPOR 19th and 20th Annual European Congresses. He was also a Congress President of the 6th Adriatic Congress of Pharmacoeconomics and Outcomes Research in 2016. 

He is the recipient of the following awards in the field of health policy and health economics: 

  • 2016 Outstanding Paper Award at the 35th International Conference on Organizational Science Development for the research paper A Srakar, R Hren, V Rupel Prevolnik “Health services utilization in older Europeans: an empirical study”. Proceedings of the 35th International Conference on Organizational Science Development, pp 997-1009, 2016. 

  • 2015 ISPOR ‘Value in Health Regional Issues Excellent Article Award’ for the research paper R Hren “Impact of the Pharma-Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010)”. Value in Health Regional Issues, 2 (2013) 290-299. 

He received his PhD in Physiology and Biophysics from Dalhousie University, Canada and an MSc in International Health Policy (Health Economics) with Distinction from London School of Economics and Political Science, UK, while he was a post-doctoral Fellow at Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah Medical School, USA. In total, his publications gathered 352/457 citations (excluding self-citations) in WoS/Scopus databases (as of January 19, 2018).